# RADIANT-2 (NCT00412061)

> Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT00412061
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Novartis Pharmaceuticals
- Conditions: Carcinoid Tumor; Malignant Carcinoid Syndrome
- Interventions: Octreotide; Placebo; Everolimus
- Enrollment: 429
- Primary outcome: Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review

## Commentary we found

- YouTube: 6
- Podcasts: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=radiant-2-nct00412061

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT00412061", "email": "<work email>"}; the inbox owner confirms by the emailed link.